BerGenBio Logo

BerGenBio

BGBIO | XOSL

Overview

Corporate Details

ISIN(s):
NO0012921180 (+2 more)
LEI:
213800TYYFXKYF3V2A23
Country:
Norway
Address:
MØLLENDALSBAKKEN 9, 5009 BERGEN
Sector:
Health Care
Industry:
Biotechnology

Description

BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including cancer and severe respiratory infections. AXL: a promising target to treat life-threatening diseases The tyrosine kinase target AXL is known to play an important role in both the innate and adaptive immune systems, BerGenBio is developing two highly selective AXL inhibitors bemcentinib and tilvestamab. Business model: R&D excellence and strategic partnerships BerGenBio is leveraging its solid leadership position in understanding the role of AXL and related kinase signalling in diseases of high unmet need to develop a diversified pipeline of selective AXL inhibitors.

Social Media

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Filings

Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-03 19:22
Regulatory News Service
BerGenBio ASA: Update on Strategic Review Process and Status of Activities
English 2.6 KB
2025-06-03 15:55
General Meeting Notice
BerGenBio ASA: Notice of Annual General Meeting - Attachment: Notice_of_AGM_Ber…
Norwegian 424.8 KB
2025-06-03 15:55
General Meeting Notice
BerGenBio ASA: Notice of Annual General Meeting
English 2.6 KB
2025-04-30 07:51
Regulatory News Service
Financial calendar
English 666 bytes
2025-04-29 20:03
Annual Report
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Rep…
English 3.9 MB
2025-04-29 20:03
Annual Report
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Rep…
English 2.8 MB
2025-04-29 20:03
Annual Report
BerGenBio ASA: Board approval of 2024 Annual financial statement and Annual Rep…
English 2.6 KB
2025-03-26 06:00
Regulatory News Service
BerGenBio announces Nature Communications Publication of BGBC003 Ph2 data in re…
English 3.9 KB
2025-03-17 06:00
Regulatory News Service
BerGenBio announces advancement of its strategic review
English 2.8 KB
2025-02-26 06:00
Earnings Release
BerGenBio Fourth Quarter Results 2024
English 926.7 KB
2025-02-26 06:00
Earnings Release
BerGenBio Fourth Quarter Results 2024
English 4.9 KB
2025-02-25 18:58
Regulatory News Service
BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of…
English 4.5 KB
2025-02-25 18:58
Regulatory News Service
BerGenBio avslutter 1L STK11m NSCLC-studie og vil utforske strategiske alternat…
Norwegian 4.5 KB
2025-02-24 07:13
Transaction in Own Shares
BerGenBio - Disclosure of shareholding
English 702 bytes
2025-02-18 06:00
Earnings Release
BerGenBio ASA: Invitation to fourth quarter 2024 results webcast
English 2.7 KB

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo 1NKEMIA Spain IKM
2cureX AB Logo 2cureX AB Sweden 2CUREX
4SC AG Logo 4SC AG Germany VSC
Abera Bioscience AB Logo Abera Bioscience AB Sweden ABERA
ABIONYX Pharma Logo ABIONYX Pharma France ABNX
Abliva Logo Abliva Sweden ABLI
AB Science Logo AB Science France AB
Acticor Biotech Logo Acticor Biotech France ALACT
Active Biotech Logo Active Biotech Sweden ACTI
AcuCort AB Logo AcuCort AB Sweden ACUC